LEADER 03758nam  2200601Ia 450 
001 9910806279603321
005 20230626234509.0
035   $a(CKB)1000000000450725
035   $a(EBL)3377460
035   $a(SSID)ssj0000121215
035   $a(PQKBManifestationID)11910125
035   $a(PQKBTitleCode)TC0000121215
035   $a(PQKBWorkID)10092857
035   $a(PQKB)10465469
035   $a(MiAaPQ)EBC3377460
035   $a(Au-PeEL)EBL3377460
035   $a(CaPaEBR)ebr10071490
035   $a(OCoLC)923270744
035   $a(EXLCZ)991000000000450725
100   $a20050323d1995      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 04$aThe children's vaccine initiative $econtinuing activities : a summary of two workshops held September 12-13 and October 25-26, 1994 /$fGreg W. Pearson, editor ; Steering Committee on the Children's Vaccine Initiative: Continuing Activities, Division of Health Promotion and Disease Prevention, Institute of Medicine
210  1$aWashington, D.C. :$cNational Academy Press,$d1995.
215   $a1 online resource  (x, 55 pages)
300   $aCommittee chair: Caroline Breese Hall.
300   $aSupport for this project was provided by the Agency for International Development.
300   $aA summary of two workshops held September 12-13 and October 25-26, 1994.
311 0 $a0-309-57234-7 
327   $a""The Children's Vaccine Initiative: Continuing Activities""; ""Copyright""; ""Preface""; ""Contents""; ""Promise and Problems: Hib, Pneumococcal, and Meningococcal Vaccines in the Developing World""; ""INTRODUCTION""; ""ARI AND MENINGOCOCCAL MENINGITIS IN THE DEVELOPING WORLD""; ""DETERMINING VACCINE NEED""; ""OVERCOMING SCIENTIFIC AND TECHNOLOGICAL BARRIERS""; ""Pneumococcal Vaccines""; ""Meningococcal Vaccines""; ""PROVING VACCINE EFFICACY: THE CHALLENGE OF DEVELOPING-COUNTRY FIELD TRIALS""; ""The Public-/Private-Sector Interface""; ""INTRODUCING AN EFFECTIVE VACCINE""
327   $a""Involving the U.S. Public and Private Sectors in the CVI""""INTRODUCTION""; ""BRINGING CLARITY TO THE CVI VISION""; ""TRENDS IN THE GLOBAL VACCINE SITUATION""; ""Industry Characteristics""; ""Local Production and Self-Sufficiency""; ""RESHAPING THE EPI""; ""A ROLE FOR INDUSTRY""; ""Barriers to Participation""; ""FACILITATING GREATER U.S. INVOLVEMENT""; ""Differential Pricing""; ""Technology Transfer""; ""DISCUSSION SUMMARY""; ""Appendix A Promise and Problems: Hib, Pneumococcal, and Meningococcal Vaccines in the Developing World""; ""FINAL AGENDA""; ""Day 1""; ""Day 2""
327   $a""WORKSHOP SPEAKERS""""WORKSHOP PARTICIPANTS""; ""Staff""; ""Appendix B Involving the U.S. Public and Private Sectors in the CVI""; ""FINAL AGENDA""; ""Day 1""; ""Involving the U.S. Public and Private Sectors in the CVI""; ""WORKSHOP SPEAKERS""; ""COMMISSIONED PAPER""; ""WORKSHOP PARTICIPANTS""; ""Staff""; ""Appendix C Acronyms and Abbreviations""
606   $aVaccination of children
606   $aVaccines
606   $aImmunization of children
615  0$aVaccination of children.
615  0$aVaccines.
615  0$aImmunization of children.
676   $a614.47
701   $aPearson$b Greg W$01636679
701   $aHall$b Caroline Breese$01636680
712 02$aInstitute of Medicine (U.S.).$bSteering Committee on the Children's Vaccine Initiative: Continuing Activities.
712 02$aInstitute of Medicine (U.S.).$bDivision of Health Promotion and Disease Prevention.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910806279603321
996   $aThe children's vaccine initiative$93978063
997   $aUNINA